Second Generation Antipsychotics

D2 receptor activity is central to reducing psychotic symptoms such as hallucinations, delusions, and disorganized thinking. Effects at serotonin 5-HT2A receptors add another component to the pharmacological profile rather than relying on dopamine signaling alone. Considering both receptor systems helps explain why these medications can produce therapeutic effects while also presenting a varied adverse-effect profile.

Some agents do not act solely by reducing dopamine D2 receptor activity; they are partial agonists at selected dopamine receptors. This represents a distinct form of dopamine signaling modulation within the drug class. The distinction matters pharmacologically because not every agent produces its effects through the same receptor action, even when the medications share treatment roles.

Clinical benefit must be balanced against weight gain, metabolic changes, sedation, and movement-related symptoms. These effects can influence the overall suitability of treatment even when hallucinations, delusions, or disorganized thinking improve. Pharmacological decision-making therefore requires attention to both the intended change in neurotransmitter signaling and the possible consequences of that change.

Their pharmacological profile includes dopamine D2 activity together with effects on serotonin receptors, particularly 5-HT2A, and in some cases partial agonism at selected dopamine receptors. This combination distinguishes them from an approach described only in terms of dopamine reduction. The broader receptor activity provides important context for understanding both clinical effects and adverse-effect tradeoffs.

These medications are used in schizophrenia and bipolar disorder, and some agents are also used as adjunctive treatment for major depressive disorder. Their applications therefore extend beyond a single diagnosis, although the specific role varies by agent. The range of indications reflects their ability to influence neurotransmitter signaling relevant to psychotic and mood symptoms.

Improvement may include reductions in hallucinations, delusions, and disorganized thinking. In mood-disorder treatment, the relevant context includes schizophrenia, bipolar disorder, or adjunctive management of major depressive disorder, depending on the agent. Evaluating these outcomes alongside sedation, metabolic changes, weight gain, and movement-related symptoms helps characterize the overall therapeutic result.